503A compounding pharmacy
Prescription-first pharmacy, not a product catalog.
RonanRx prepares medication only after a licensed clinician writes for an identified patient and a pharmacist approves the prescription.
What 503A is
A state-licensed pharmacy that prepares medication for one named patient at a time.
A 503A pharmacy is the traditional compounding model: a doctor writes a prescription for an identified patient, and a licensed pharmacist decides whether the pharmacy can prepare it safely and lawfully.
RonanRx works in that lane. We do not run a catalog, ship office stock, or fill bulk orders. The prescription, the patient, the formulation, the state rules, and the pharmacist's judgment all matter before anything is prepared.
Patient-specific prescriptions
By name, by evaluation, by prescription.
Compounded medication from a 503A pharmacy is dispensed only on a valid prescription written for an identified individual patient. Not bulk supply. Not office stock. Not consumer self-ordering.
Every patient-specific prescription is reviewed by a pharmacist before compounding. Supporting clinical rationale may be requested. The pharmacist has independent release authority and can decline a prescription that does not fit the pharmacy's legal, sourcing, formulation, or safety threshold.
503A vs 503B
Two different categories. Different rules.
503A means traditional compounding pharmacies. State-licensed. Patient-specific prescriptions. Prepared one patient at a time. RonanRx operates here.
503B means outsourcing facilities. FDA-registered. May prepare medication in bulk for office use. Different oversight, different scope, different use case.
Both have a place. RonanRx is 503A: prescription-driven pharmacy work for a named patient, not bulk supply.
How safety is controlled
Accountability is the point.
The safety chain starts with a valid prescription and pharmacist review. It continues through active-ingredient sourcing, formulation feasibility, weighing and preparation records, sterility controls when a preparation is sterile, labeled patient instructions, and recallable lot history.
USP 795 and USP 797 are the technical rulebooks for nonsterile and sterile compounding. In plain English: the pharmacy has written processes for how a preparation is made, checked, labeled, stored, and traced back if something needs review.
Category 2 peptide requests
Physician submission does not mean automatic dispensing.
Category 1 and Category 2 are FDA review buckets for nominated bulk drug substances, not consumer-access labels. Category 1 means a nominated substance remains in FDA's interim review pathway. Category 2 means FDA has enough information to evaluate the substance, but has also identified significant safety risks pending further review, so FDA does not treat it like Category 1.
Physicians may submit patient-specific prescription requests for pharmacy review. Certain preparations may be available now when clinically appropriate, lawfully prescribed, and approved by the dispensing pharmacy. Availability is determined case by case.
RonanRx is monitoring FDA's PCAC process and any subsequent agency action. Availability may change after FDA review, PCAC discussion, final agency action, or state-board guidance. Valid patient-specific prescription required. No consumer self-ordering, no office stock, no bulk dispensing.
Compounded drugs are not FDA-approved. They are prepared for identified patients based on lawful prescribing and patient-specific need. They are not generic equivalents of approved drugs and should not be evaluated using branded-drug trial data alone. Availability varies by state, prescribed medication, ingredient status, and pharmacist review.
More context
Plain-language explainers.
Why it matters for your patients, and what it changes for you as the prescribing doctor.